Our findings provide insights to potential molecular mechanisms of persistent inflammation in PASC and suggest possible therapeutic targets that may be efficacious including JAK inhibitors or specific cytokine blockade in individuals that have the persistent inflammatory protein signature (TNF, IL-6, IFN-γ, etc). This evidence concerns the gene IL6 and long COVID-19.